Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers

JAMA Neurology

Volumn 71, Issue 12, 2014, Pages 1481-1489

  Liu, Qing ^a   Waltz, Shannon ^a   Woodruff, Grace ^b   Ouyang, Joe ^b,c   Israel, Mason A ^b,d   Herrera, Cheryl ^b   Sarsoza, Floyd ^a   Tanzi, Rudolph E ^e   Koo, Edward H ^a   Ringman, John M ^f   Goldstein, Lawrence S B ^b   Wagner, Steven L ^a   Yuan, Shauna H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Capitalbio   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 34; AMYLOID BETA PROTEIN 37; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN 39; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; BETA TUBULIN; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; MAP2B PROTEIN; MEMBRANE PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PRESENILIN 1; SEMAGACESTAT; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ALANINE; AMYLOID BETA-PROTEIN (1-42); AZEPINE DERIVATIVE; BIOLOGICAL MARKER; N2-((2S)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYETHANOYL)-N1-((7S)-5-METHYL-6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-L-ALANINAMIDE; PEPTIDE FRAGMENT; PSEN1 PROTEIN, HUMAN; SECRETASE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; PLURIPOTENT STEM CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; PS1 GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NERVE CELL;

ALANINE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS; AZEPINES; BIOMARKERS; HETEROZYGOTE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTATION; NEURONS; PEPTIDE FRAGMENTS; PRESENILIN-1;

EID: 84918522964     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2482     Document Type: Article

References (31)

1. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3(77):sr1.
2. Berk C, Sabbagh MN. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging. 2013;30(10):783-792.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.
4. Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells: opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011;10(12):915-929.
5. Chávez-Gutiérrez L, Bammens L, Benilova I, et al. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10):2261-2274.
6. Yuan SH, Shaner M. Bioengineered stem cells in neural development and neurodegeneration research. Ageing Res Rev. 2013;12(3):739-748.
7. Kounnas MZ, Danks AM, Cheng S, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron. 2010;67(5):769-780.
8. Lee G, Ramirez CN, Kim H, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012;30(12):1244-1248.
9. Peng J, Liu Q, Rao MS, Zeng X. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen. 2013;18(5):522-533.
10. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
11. Chan EM, Ratanasirintrawoot S, Park IH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol. 2009;27(11):1033-1037.
12. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795-797.
13. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482(7384):216-220.
14. Yuan SH, Martin J, Elia J, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One. 2011;6(3):e17540.
15. Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28(1):31-40.
16. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275-280.
17. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
18. Koch P, Tamboli IY, Mertens J, et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. Am J Pathol. 2012;180(6):2404-2416.
19. Mitani Y, Yarimizu J, Saita K, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32(6):2037-2050.
20. Oehlrich D, Berthelot DJC, Gijsen HJ. γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem. 2011;54(3):669-698.
21. Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27(7):686-695.
22. Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra177.
23. Serneels L, Van Biervliet J, Craessaerts K, et al. Gamma-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324(5927):639-642.
24. Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7(3):172-178.
25. Wagner SL, Zhang C, Cheng S, et al. Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry. 2014;53(4):702-713.
26. Takami M, Nagashima Y, Sano Y, et al. Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042-13052.
27. Okochi M, Tagami S, Yanagida K, et al. γ-Secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. Cell Rep. 2013;3(1):42-51.
28. Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry. 2013;52(19):3197-3216.
29. Kretner B, Fukumori A, Gutsmiedl A, et al. Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem. 2011;286(17):15240-15251.
30. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69(11):1430-1440.
31. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99.